» Articles » PMID: 33795879

Detection of Respiratory Syncytial Virus Defective Genomes in Nasal Secretions is Associated with Distinct Clinical Outcomes

Abstract

Respiratory syncytial virus (RSV) causes respiratory illness in children, immunosuppressed individuals and the elderly. However, the viral factors influencing the clinical outcome of RSV infections remain poorly defined. Defective viral genomes (DVGs) can suppress virus replication by competing for viral proteins and by stimulating antiviral immunity. We studied the association between detection of DVGs of the copy-back type and disease severity in three RSV A-confirmed cohorts. In hospitalized children, detection of DVGs in respiratory samples at or around the time of admission associated strongly with more severe disease, higher viral load and a stronger pro-inflammatory response. Interestingly, in experimentally infected adults, the presence of DVGs in respiratory secretions differentially associated with RSV disease severity depending on when DVGs were detected. Detection of DVGs early after infection associated with low viral loads and mild disease, whereas detection of DVGs late after infection, especially if DVGs were present for prolonged periods, associated with high viral loads and severe disease. Taken together, we demonstrate that the kinetics of DVG accumulation and duration could predict clinical outcome of RSV A infection in humans, and thus could be used as a prognostic tool to identify patients at risk of worse clinical disease.

Citing Articles

A measles virus collective infectious unit that caused lethal human brain disease includes many locally restricted and few widespread copy-back defective genomes.

Taye B, Yousaf I, Navaratnarajah C, Schroeder D, Pfaller C, Cattaneo R J Virol. 2024; 98(11):e0123224.

PMID: 39431848 PMC: 11575405. DOI: 10.1128/jvi.01232-24.


Identification of distinct genotypes in circulating RSV A strains based on variants in the virus replication-associated genes.

Musa A, Faber S, Forrest K, Smith K, Sengupta S, Lopez C J Virol. 2024; 98(8):e0099024.

PMID: 39007617 PMC: 11334426. DOI: 10.1128/jvi.00990-24.


Influenza A defective viral genomes and non-infectious particles are increased by host PI3K inhibition via anti-cancer drug alpelisib.

Agu I, Jose I, Ram A, Oberbauer D, Albeck J, Diaz Munoz S bioRxiv. 2024; .

PMID: 39005364 PMC: 11245024. DOI: 10.1101/2024.07.03.601932.


Generation of Defective Interfering Particles of Morbilliviruses Using Reverse Genetics.

Rennick L, Duprex W, Tilston-Lunel N Methods Mol Biol. 2024; 2808:57-70.

PMID: 38743362 DOI: 10.1007/978-1-0716-3870-5_5.


Identification of distinct genotypes in circulating RSV A strains based on variants on the virus replication-associated genes.

Musa A, Faber S, Forrest K, Smith K, Sengupta S, Lopez C bioRxiv. 2024; .

PMID: 38712045 PMC: 11071361. DOI: 10.1101/2024.04.22.590570.


References
1.
Hall C, Weinberg G, Iwane M, Blumkin A, Edwards K, Staat M . The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360(6):588-98. PMC: 4829966. DOI: 10.1056/NEJMoa0804877. View

2.
Falsey A, Hennessey P, Formica M, Cox C, Walsh E . Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352(17):1749-59. DOI: 10.1056/NEJMoa043951. View

3.
Shi T, McAllister D, OBrien K, Simoes E, Madhi S, Gessner B . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390(10098):946-958. PMC: 5592248. DOI: 10.1016/S0140-6736(17)30938-8. View

4.
Meissner H, Welliver R, Chartrand S, Law B, Weisman L, Dorkin H . Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999; 18(3):223-31. DOI: 10.1097/00006454-199903000-00004. View

5.
Schmidt R, Majer I, Garcia Roman N, Rivas Basterra A, Grubb E, Medrano Lopez C . Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Econ Rev. 2017; 7(1):47. PMC: 5736509. DOI: 10.1186/s13561-017-0181-3. View